Dr Ronan Lordan

Available to discuss new collaborations, science communication, outreach or speaking opportunities. Contact via email.



School of Pharmacy and Biomolecular Sciences, FutureNeuro Research Ireland Center, Royal College of Surgeons in Ireland (RCSI). Dublin, Ireland.



Concomitant COX-1 and COX-2 suppression is not sufficient to induce enteropathy associated with chronic NSAID use.


Journal article


Kayla Barekat, Soumita Ghosh, Christin Herrmann, Karl Keat, C. Assenmacher, Ceylan Tanes, Naomi Wilson, R. Lordan, Antonijo Mrcela, Lubica Rauova, Arjun Sengupta, U. S. Das, Robin Joshi, E. Friedman, Marylyn D. Ritchie, K. Bittinger, A. Weljie, Ken Cadwell, Frederic D. Bushman, Gary D. Wu, G. Fitzgerald, E. Ricciotti
Journal of Clinical Investigation, 2026

Semantic Scholar DOI PubMed
Cite

Cite

APA   Click to copy
Barekat, K., Ghosh, S., Herrmann, C., Keat, K., Assenmacher, C., Tanes, C., … Ricciotti, E. (2026). Concomitant COX-1 and COX-2 suppression is not sufficient to induce enteropathy associated with chronic NSAID use. Journal of Clinical Investigation.


Chicago/Turabian   Click to copy
Barekat, Kayla, Soumita Ghosh, Christin Herrmann, Karl Keat, C. Assenmacher, Ceylan Tanes, Naomi Wilson, et al. “Concomitant COX-1 and COX-2 Suppression Is Not Sufficient to Induce Enteropathy Associated with Chronic NSAID Use.” Journal of Clinical Investigation (2026).


MLA   Click to copy
Barekat, Kayla, et al. “Concomitant COX-1 and COX-2 Suppression Is Not Sufficient to Induce Enteropathy Associated with Chronic NSAID Use.” Journal of Clinical Investigation, 2026.


BibTeX   Click to copy

@article{kayla2026a,
  title = {Concomitant COX-1 and COX-2 suppression is not sufficient to induce enteropathy associated with chronic NSAID use.},
  year = {2026},
  journal = {Journal of Clinical Investigation},
  author = {Barekat, Kayla and Ghosh, Soumita and Herrmann, Christin and Keat, Karl and Assenmacher, C. and Tanes, Ceylan and Wilson, Naomi and Lordan, R. and Mrcela, Antonijo and Rauova, Lubica and Sengupta, Arjun and Das, U. S. and Joshi, Robin and Friedman, E. and Ritchie, Marylyn D. and Bittinger, K. and Weljie, A. and Cadwell, Ken and Bushman, Frederic D. and Wu, Gary D. and Fitzgerald, G. and Ricciotti, E.}
}

Abstract

Nonsteroidal anti-inflammatory drugs (NSAIDs) are the most widely used medications for the management of chronic pain; however, they are associated with numerous gastrointestinal (GI) adverse events. Although many mechanisms have been suggested, NSAID-induced enteropathy has been thought to be primarily due to inhibition of both cyclooxygenases (COX) -1 and -2, which results in suppression of prostaglandin synthesis. Yet surprisingly, we found that concomitant postnatal deletion of Cox-1 and -2 over 10 months failed to cause intestinal injury in mice unless they were treated with naproxen or its structural analog, phenylpropionic acid, which is not a COX inhibitor. Cox double knockout mice exhibit a distinct gut microbiome composition and cohousing them with controls rescues their dysbiosis and delays the onset of NSAID-induced GI bleeding. In both the UK Biobank and All of Us human cohorts, coadministration of antibiotics with NSAIDs is associated with an increased frequency of GI bleeding. These results show that prostaglandin suppression plays a trivial role in NSAID-induced enteropathy. However, Cox deletion causes dysbiosis of the gut microbiome that amplifies the enteropathic response to NSAIDs.


Share

Tools
Translate to